The number of vaccine doses sent depends on the population in the country. However, the arrangements for the practical side of vaccine delivery are included in contracts signed by individual member states, explains European Commission spokesman Stefan de Keersmaecker. It adds that the European Commission “is not party to agreements between the company and the Member States”.
Pfizer announced last week that temporarily reduce the supply of COVID-19 vaccines for the whole of Europe following changes made at the company’s Puurs plant in Belgium. Some people blame the European Union for the vaccine shortage. – Unfortunately, the European Commission has ordered too few vaccines – said Adam Bielan, PiS MEP, in “Kropka nad i” on TVN24.
In response to questions from Konkret24 journalists, European Commission spokesman Stefan de Keersmaecker explained that Pfizer “declared within a week to return to the earlier pace of deliveries and increase it from mid-February”. “It is important for European Union citizens that the prescribed number of doses of the COVID-19 vaccine is delivered in accordance with the contract, not only because of the increase in infections, but also because of the need to ensure the right number of doses for the first and second doses” – by Stefan de Keersmaecker.
“The Commission is not party to agreements between the company and the Member States”
“The number of doses sent depends on the population in a given country. However, the arrangements for the practical side of vaccine delivery are included in the contracts signed by individual member states” – noted the spokesman for the European Commission. “This is due to the fact that the supply of vaccines is related to the organization of vaccination in the Member States. It is the Member States that are best able to agree with the company how many doses should be delivered, when and where. added.
Stefan de Keersmaecker pointed out that member states can simultaneously negotiate the redistribution of doses among themselves. “The starting point is a proportional split on the basis of population, but some member states may want more, others less. These discussions are left to member states,” he said.
Centralized EU approach
European Union Member States have decided on a centralized EU approach to securing supplies and supporting the development of a COVID-19 vaccine. The European Commission, on behalf of the Member States, enters into advance purchase agreements with individual vaccine manufacturers and funds part of the start-up costs that manufacturers have to bear.
Once a vaccine is approved for use in the European Union, all Member States have access to it simultaneously. Deliveries are distributed among countries in proportion to the number of inhabitants.
Main photo source: GUILLAUME HORCAJUELO / PAP / EPA